Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Bausch + Lomb Moves to Acquire Whitecap, InflammX to Expand Clinical Pipeline
Bausch + Lomb recently made moves to acquire two companies that it says will strengthen its expanding pipeline and help address unmet needs in ophthalmology. The company announced Jan. 13 that an a...
Dual Inflammasome Inhibiting Implant Shows Positive Phase I/II Results in GA
Inflammasome Therapeutics reported on Jan. 15 positive topline three-month data from a Phase I/II trial of its K8 dual inflammasome inhibiting implant in geographic atrophy (GA). In the study of fi...
Study Shows Promise for Genetic Base Editing in Stargardt Disease
Researchers from Switzerland’s Institute of Molecular and Clinical Ophthalmology Basel and Beam Therapeutics say they have developed a gene editing therapy that could potentially treat Stargardt di...
Tarsus Will Advance Lotilaner Eyelid Gel for Ocular Rosacea
Tarsus Pharmaceuticals, of Irvine, California, announced Jan. 13 that it would advance TP-04, an ophthalmic gel formulation of lotilaner, targeting ocular rosacea. Tarsus, maker of Xdemvy eye drops...
Bausch + Lomb to Collaborate with Character Bio, City Therapeutics in AMD, GA
Bausch + Lomb recently made deals to collaborate with two companies that it says will bolster its expanding pipeline and help address unmet needs in ophthalmology. Character Biosciences reported on...
Bausch + Lomb Launches EnVista Aspire Monofocal-Plus IOLs in Europe
On Jan. 13, Bausch + Lomb announced the launch of its enVista Aspire intermediate-optimized monofocal and toric intraocular lenses, often referred to as monofocal-plus IOLs, in the EU. The IOLs lau...
Teva Signs Deal to Commercialize Formycon’s Aflibercept Biosimilar Candidate in Israel and Most of Europe
Israel’s Teva Pharmaceuticals announced Jan. 13 that it had entered into a collaboration with German companies Klinge Biopharma and Formycon for the semi-exclusive commercialization of FYB203, Form...
Valo Health Suspends Work on Oral DR Candidate After Phase II Trial Misses Endpoints
Valo Health reported Dec. 31 that OPL-0401, its oral diabetic retinopathy treatment candidate, missed its primary and secondary endpoints of improvement in Diabetic Retinopathy Severity Scale score...
Aviceda Raises $207.5 Million in Upsized Series C Round to Advance GA Candidate
Aviceda Therapeutics announced Jan. 7 that it had raised $207.5 million in an upsized Series C funding round. The Cambridge, Massachusetts, company said proceeds would support an ongoing Phase IIb/...
Eyebright Medical Gains Certification in China for Phakic IOL
China’s Eyebright Medical announced Jan. 7 that its phakic intraocular lens, the Loong Crystal PR, had received certification as a Class III medical device from the country’s National Medical Produ...
Low-Vision Devices, Including One Similar to a Fly’s Eye, Highlighted at CES 2025
The 2025 Consumer Electronics Show featured at least two wearable devices intended to improve vision for those who are vision impaired or legally blind. The conference was held Jan. 7-10 in Las Veg...
US FDA Grants Rare Pediatric Disease Designation to ViGeneron’s RP Gene Therapy Candidate
Germany’s ViGeneron announced Jan. 8 that the US FDA had granted rare pediatric disease designation to VG901, a gene therapy candidate targeting retinitis pigmentosa (RP) caused by mutations in the...
Past News Stories
Eyenuk Appoints Gaurav Agarwal as Chief Executive Officer
Digital health care company Eyenuk, of Los Angeles, California, announced Jan. 6 that it had appointed Gaurav Agarwal as chief executive officer. Agarwal was previously the head of product and cust...
Unity Biotechnology Appoints Federico Grossi, MD, PhD, as Chief Medical Officer
Unity Biotechnology announced Jan. 6 that it had appointed Federico Grossi, MD, PhD, as chief medical officer. Grossi was most recently chief medical officer at Apellis Pharmaceuticals, where he he...
Xbrane Resubmits BLA to US FDA for Ranibizumab Biosimilar
Sweden’s Xbrane Biopharma announced Dec. 31 that it had resubmitted the biologics license application (BLA) to the US FDA for its Lucentis (ranibizumab) biosimilar candidate. The FDA issued a compl...
Ophthalmic Revenue Roundup for Carl Zeiss Meditec, Amgen, Biogen
Carl Zeiss Meditec reported Dec. 11 that ophthalmology revenue for its full fiscal year 2023/2024, which ended Sept. 30, was €1.59 billion (US $1.7 billion, converted Dec. 11, 2024), an increase of...
ViGeneron Gains US FDA Green Light to Begin Phase I/II Trial of Gene Therapy Candidate for Stargardt
Germany’s ViGeneron announced Dec. 18 that the US FDA had cleared its investigational new drug (IND) application for a Phase I/II study of VG801, a gene therapy candidate to treat Stargardt disease...
EssilorLuxottica to Acquire Espansione Group, Maker of Ophthalmic Devices
Eyewear conglomerate EssilorLuxottica announced Dec. 16 that it had entered into an agreement to acquire Espansione Group, an Italian maker of light-based ophthalmic devices. Financial details and ...
SightStream is Developing an Eye Drop Candidate for Corneal Endothelial Disease
SightStream Biotherapeutics, an ophthalmic drug development company spun out of Harvard University in 2020, is raising $7.5 million in Series A funding to advance its preclinical melanocortin recep...
Children’s Hospital Los Angeles Celebrates 100th Luxturna Procedure
Children’s Hospital Los Angeles (CHLA) marked a milestone recently, completing its 100th procedure with the retinal gene therapy Luxturna for Leber congenital amaurosis (LCA)—the most of any center...
US FDA Grants Rare Pediatric Disease Designation to EyeDNA’s RP Gene Therapy Candidate
France’s eyeDNA Therapeutics announced Dec. 17 that the US FDA had granted rare pediatric disease designation for HORA-PDE6b, its gene therapy candidate for PDE6b-associated retinitis pigmentosa (R...
Carter’s Many Accomplishments Include Saving Millions from Blindness
Former US president Jimmy Carter’s many legacies include saving the of sight of millions of people in less developed regions by providing treatment for onchocerciasis and trachoma through his Carte...
Glaukos Submits NDA for Epioxa Epi-On Crosslinking Treatment
Glaukos, of Aliso Viejo, California, reported Dec. 23 that it had submitted its new drug application to the US FDA for Epioxa, an epi-on version of the company’s iLink corneal crosslinking therapy,...
Alcon Recalls Single Lot of Systane Ultra PF Drops Over Fungal Contamination
The US FDA announced on Dec. 21 that Alcon was voluntarily recalling a single lot of Systane Lubricant Eye Drops Ultra PF over possible fungal contamination. Systane Ultra PF is used for the tempor...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.